The Complex Interaction between Proton Pump Inhibitors and Cancer Treatment

Chen, Hao; Kondo, Masaaki; Horita, Nobuyuki; Takahashi, Kenichi; Kaneko, Takeshi

doi:10.3390/cancers15225346

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have explored the impact of PPIs usage on the efficacy and safety of EGFR-TKIs in NSCLC patients, and reported a reduction in the effectiveness of EGFR-TKIs with shorter PFS and OS. 32,33 Our study found that 41.9% NSCLC patients had concomitant use of afatinib and PPIs. The proportion of patients receiving the coadministration of afatinib and PPIs was not significantly different between the PFS > 36 months group and the PFS ≤36 months group (45.2% vs. 41.3%; p = 0.506).…”

Section: Discussionmentioning

confidence: 74%

Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Chiu,

Hsu,

Wang

et al. 2024

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThis study aimed to investigate the factors associated with prolonged progression‐free survival (PFS) (>36 months) of advanced non‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations treated with first‐line afatinib.MethodsWe performed a retrospective analysis of data of patients with advanced EGFR‐mutated NSCLC receiving first‐line afatinib at two tertiary care referral centers, Linkou and Kaohsiung Chang Gung Memorial Hospital, in Taiwan between June 2014 and April 2022.ResultsThe data of 546 treatment‐naïve EGFR‐mutated advanced NSCLC patients were analyzed. Median PFS and overall survival were 14.5 months and 27.2 months, respectively. The PFS of 462 patients (84.6%) was less than 36 months and of 84 patients (15.4%) was more than 36 months. The PFS > 36 months group had a significantly higher percentage of patients with uncommon mutations (p = 0.002). The PFS ≤36 months group had significantly higher incidences of bone, liver, and adrenal metastases (all p < 0.05) and a higher rate of multiple distant metastases. Multivariate logistic regression analysis showed that liver metastasis was negatively and independently associated with prolonged PFS (adjusted odds ratio = 0.246 [95% CI: 0.067–0.908], p = 0.035). The median overall survival of the PFS >36 months group was 46.0 months and that of the PFS ≤36 months group was 22.9 months (log‐rank test, p < 0.001).ConclusionsWe found that EGFR‐mutated NSCLC patients receiving first‐line afatinib were prone to shorter PFS if they had distant organ metastasis, especially liver metastasis.

show abstract

Section: Discussionmentioning

confidence: 74%